References

Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial

10.1001/jamaoncol.2020.7932 · ExternalCitation · doi-reference

Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial

10.1001/jamaoncol.2022.5370 · ExternalCitation · doi-reference

Controlled inflammation drives neutrophil-mediated precision drug delivery in heterogeneous tumors

10.1002/advs.202411307 · ExternalCitation · doi-reference

Recent advances in biomimetic aggregation-induced emission photosensitizers for photodynamic therapy and immunotherapy

10.1002/bmm2.12076 · ExternalCitation · doi-reference

Metal coordination-driven assembly of stimulator of interferon genes-activating nanoparticles for tumor chemo-immunotherapy

10.1002/bmm2.12077 · ExternalCitation · doi-reference

Regulated cell death-amplified sonodynamic anti-tumor immune nanotherapeutics

10.1002/bmm2.12079 · ExternalCitation · doi-reference

Designing next-generation immune cell therapies with nanomaterials

10.1002/bmm2.70003 · ExternalCitation · doi-reference

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer

10.1002/cncr.32445 · ExternalCitation · doi-reference

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

10.1007/s00262-013-1396-8 · ExternalCitation · doi-reference

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

10.1007/s00262-022-03191-8 · ExternalCitation · doi-reference

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

10.1007/s10637-023-01410-2 · ExternalCitation · doi-reference

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

10.1016/j.annonc.2023.07.006 · ExternalCitation · doi-reference

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma

10.1016/j.annonc.2026.04.010 · ExternalCitation · doi-reference

Visualizing synaptic transfer of tumor antigens among dendritic cells

10.1016/j.ccell.2020.05.002 · ExternalCitation · doi-reference

Spatiotemporal co-dependency between macrophages and exhausted CD8(+) T cells in cancer

10.1016/j.ccell.2022.05.004 · ExternalCitation · doi-reference

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

10.1016/j.ccell.2022.08.003 · ExternalCitation · doi-reference

IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer

10.1016/j.ccell.2022.11.014 · ExternalCitation · doi-reference

Neutrophil-activating therapy for the treatment of cancer

10.1016/j.ccell.2023.01.002 · ExternalCitation · doi-reference

Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation

10.1016/j.ccell.2023.03.008 · ExternalCitation · doi-reference

A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity

10.1016/j.ccell.2023.06.008 · ExternalCitation · doi-reference

In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases

10.1016/j.ccell.2023.09.014 · ExternalCitation · doi-reference

Interferon-stimulated neutrophils as a predictor of immunotherapy response

10.1016/j.ccell.2023.12.005 · ExternalCitation · doi-reference

Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer

10.1016/j.ccell.2023.12.012 · ExternalCitation · doi-reference

Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity

10.1016/j.ccell.2024.06.014 · ExternalCitation · doi-reference

Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD

10.1016/j.ccell.2024.07.007 · ExternalCitation · doi-reference

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

10.1016/j.ccell.2024.10.007 · ExternalCitation · doi-reference

Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity

10.1016/j.ccell.2024.10.014 · ExternalCitation · doi-reference

Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases

10.1016/j.ccell.2025.01.008 · ExternalCitation · doi-reference

Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps

10.1016/j.ccell.2025.06.007 · ExternalCitation · doi-reference

LXR/ApoE activation restricts innate immune suppression in cancer

10.1016/j.cell.2017.12.026 · ExternalCitation · doi-reference

NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control

10.1016/j.cell.2018.01.004 · ExternalCitation · doi-reference

Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells

10.1016/j.cell.2018.10.014 · ExternalCitation · doi-reference

Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity

10.1016/j.cell.2019.02.005 · ExternalCitation · doi-reference

TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy

10.1016/j.cell.2020.07.013 · ExternalCitation · doi-reference

Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction

10.1016/j.cell.2020.09.015 · ExternalCitation · doi-reference

A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells

10.1016/j.cell.2021.01.010 · ExternalCitation · doi-reference

Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer

10.1016/j.cell.2021.07.029 · ExternalCitation · doi-reference

Spatially organized multicellular immune hubs in human colorectal cancer

10.1016/j.cell.2021.08.003 · ExternalCitation · doi-reference

Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer

10.1016/j.cell.2022.02.021 · ExternalCitation · doi-reference

A neutrophil response linked to tumor control in immunotherapy

10.1016/j.cell.2023.02.032 · ExternalCitation · doi-reference

T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants

10.1016/j.cell.2023.03.007 · ExternalCitation · doi-reference

A pan-cancer single-cell panorama of human natural killer cells

10.1016/j.cell.2023.07.034 · ExternalCitation · doi-reference

Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death

10.1016/j.cell.2023.12.015 · ExternalCitation · doi-reference

IGSF8 is an innate immune checkpoint and cancer immunotherapy target

10.1016/j.cell.2024.03.039 · ExternalCitation · doi-reference

Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis

10.1016/j.cell.2024.09.016 · ExternalCitation · doi-reference

Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

10.1016/j.celrep.2024.114875 · ExternalCitation · doi-reference

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade

10.1016/j.ebiom.2019.02.056 · ExternalCitation · doi-reference

New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses

10.1016/j.ebiom.2020.102922 · ExternalCitation · doi-reference

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors

10.1016/j.immuni.2014.10.017 · ExternalCitation · doi-reference

Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response

10.1016/j.immuni.2018.09.016 · ExternalCitation · doi-reference

CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity

10.1016/j.immuni.2020.03.001 · ExternalCitation · doi-reference

Transcriptional and functional analysis of CD1c(+) human dendritic cells identifies a CD163(+) subset priming CD8(+)CD103(+) T cells

10.1016/j.immuni.2020.06.002 · ExternalCitation · doi-reference

β(2)-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression

10.1016/j.immuni.2021.07.002 · ExternalCitation · doi-reference

Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer

10.1016/j.immuni.2022.10.002 · ExternalCitation · doi-reference

Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma

10.1016/j.immuni.2024.04.006 · ExternalCitation · doi-reference

Cell membrane derived liposomes loaded with DNase I target neutrophil extracellular traps which inhibits colorectal cancer liver metastases

10.1016/j.jconrel.2023.04.013 · ExternalCitation · doi-reference

ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors

10.1016/j.lungcan.2025.108516 · ExternalCitation · doi-reference

Compendium of current complement therapeutics

10.1016/j.molimm.2019.07.030 · ExternalCitation · doi-reference

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity

10.1016/j.stem.2020.05.008 · ExternalCitation · doi-reference

Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer

10.1016/j.stem.2024.03.018 · ExternalCitation · doi-reference

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological Malignancies

10.1016/j.xcrm.2023.100961 · ExternalCitation · doi-reference

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

10.1016/j.xcrm.2023.101307 · ExternalCitation · doi-reference

Lymph node and tumor-associated PD-L1(+) macrophages antagonize dendritic cell vaccines by suppressing CD8(+) T cells

10.1016/j.xcrm.2023.101377 · ExternalCitation · doi-reference

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

10.1016/j.xcrm.2023.101380 · ExternalCitation · doi-reference

Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum

10.1016/j.xcrm.2024.101516 · ExternalCitation · doi-reference

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

10.1016/s0140-6736(19)30764-0 · ExternalCitation · doi-reference

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

10.1016/s0140-6736(23)02268-7 · ExternalCitation · doi-reference

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

10.1016/s0140-6736(24)02462-0 · ExternalCitation · doi-reference

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

10.1016/s0161-5890(03)00112-3 · ExternalCitation · doi-reference

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

10.1016/s1470-2045(16)00078-4 · ExternalCitation · doi-reference

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial

10.1016/s1470-2045(17)30517-x · ExternalCitation · doi-reference

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

10.1016/s1470-2045(18)30148-7 · ExternalCitation · doi-reference

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

10.1016/s1470-2045(21)00584-2 · ExternalCitation · doi-reference

Localized degradation of neutrophil extracellular traps by photoregulated enzyme delivery for cancer immunotherapy and metastasis suppression

10.1021/acsnano.1c09318 · ExternalCitation · doi-reference

Neutrophil-mediated delivery of nanocrystal drugs via photoinduced inflammation enhances cancer therapy

10.1021/acsnano.3c02013 · ExternalCitation · doi-reference

Nanoparticle retinoic acid-inducible gene I agonist for cancer immunotherapy

10.1021/acsnano.3c06225 · ExternalCitation · doi-reference

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

10.1038/nature18300 · ExternalCitation · doi-reference

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

10.1038/nature25501 · ExternalCitation · doi-reference

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

10.1038/ncomms12150 · ExternalCitation · doi-reference

Modulation of the antitumor immune response by complement

10.1038/ni.1655 · ExternalCitation · doi-reference

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells

10.1038/ni.3159 · ExternalCitation · doi-reference

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

10.1038/nm.3560 · ExternalCitation · doi-reference

Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment

10.1038/s41416-024-02710-x · ExternalCitation · doi-reference

Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

10.1038/s41423-020-0515-7 · ExternalCitation · doi-reference

Sequential STING and CD40 agonism drives massive expansion of tumor-specific T cells in liposomal peptide vaccines

10.1038/s41423-024-01249-4 · ExternalCitation · doi-reference

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B

10.1038/s41467-017-00327-8 · ExternalCitation · doi-reference

IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization

10.1038/s41467-019-10676-1 · ExternalCitation · doi-reference

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

10.1038/s41467-020-20600-7 · ExternalCitation · doi-reference

PPARγ drives IL-33-dependent ILC2 pro-tumoral functions

10.1038/s41467-021-22764-2 · ExternalCitation · doi-reference

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

10.1038/s41467-021-22929-z · ExternalCitation · doi-reference

Live tumor imaging shows macrophage induction and TMEM-mediated enrichment of cancer stem cells during metastatic dissemination

10.1038/s41467-021-27308-2 · ExternalCitation · doi-reference

Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells

10.1038/s41467-022-28076-3 · ExternalCitation · doi-reference

Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer

10.1038/s41467-022-29366-6 · ExternalCitation · doi-reference

Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity

10.1038/s41467-022-31218-2 · ExternalCitation · doi-reference

DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response

10.1038/s41467-022-34041-x · ExternalCitation · doi-reference

Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer

10.1038/s41467-022-34428-w · ExternalCitation · doi-reference

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

10.1038/s41467-023-39196-9 · ExternalCitation · doi-reference

Tumour-retained activated CCR7(+) dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

10.1038/s41467-024-44787-1 · ExternalCitation · doi-reference

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity

10.1038/s41467-024-44789-z · ExternalCitation · doi-reference

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: The MIND-DC randomized phase III trial

10.1038/s41467-024-45358-0 · ExternalCitation · doi-reference

TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in Malignant glioma: a randomized phase II trial

10.1038/s41467-024-48073-y · ExternalCitation · doi-reference

PIKfyve, expressed by CD11c-positive cells, controls tumor immunity

10.1038/s41467-024-48931-9 · ExternalCitation · doi-reference

Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice

10.1038/s41467-025-60769-3 · ExternalCitation · doi-reference

An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy

10.1038/s41467-025-61299-8 · ExternalCitation · doi-reference

Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18

10.1038/s41467-025-61324-w · ExternalCitation · doi-reference

Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial

10.1038/s41467-025-66801-w · ExternalCitation · doi-reference

The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: A single-arm, phase II study

10.1038/s41467-026-69294-3 · ExternalCitation · doi-reference

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

10.1038/s41551-018-0236-8 · ExternalCitation · doi-reference

Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy

10.1038/s41551-024-01180-z · ExternalCitation · doi-reference

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

10.1038/s41556-018-0256-3 · ExternalCitation · doi-reference

STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity

10.1038/s41563-022-01251-z · ExternalCitation · doi-reference

De novo design of potent and selective mimics of IL-2 and IL-15

10.1038/s41586-018-0830-7 · ExternalCitation · doi-reference

Fatty acid transport protein 2 reprograms neutrophils in cancer

10.1038/s41586-019-1118-2 · ExternalCitation · doi-reference

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

10.1038/s41586-019-1410-1 · ExternalCitation · doi-reference

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity

10.1038/s41586-020-2015-4 · ExternalCitation · doi-reference

Gasdermin E suppresses tumour growth by activating anti-tumour immunity

10.1038/s41586-020-2071-9 · ExternalCitation · doi-reference

A conserved dendritic-cell regulatory program limits antitumour immunity

10.1038/s41586-020-2134-y · ExternalCitation · doi-reference

DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25

10.1038/s41586-020-2394-6 · ExternalCitation · doi-reference

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

10.1038/s41586-020-2422-6 · ExternalCitation · doi-reference

cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity

10.1038/s41586-020-2611-3 · ExternalCitation · doi-reference

Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells

10.1038/s41586-021-03651-8 · ExternalCitation · doi-reference

Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

10.1038/s41586-022-04735-9 · ExternalCitation · doi-reference

STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma

10.1038/s41586-023-05880-5 · ExternalCitation · doi-reference

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

10.1038/s41586-023-06063-y · ExternalCitation · doi-reference

Non-cell-autonomous cancer progression from chromosomal instability

10.1038/s41586-023-06464-z · ExternalCitation · doi-reference

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

10.1038/s41586-023-06696-z · ExternalCitation · doi-reference

IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer

10.1038/s41586-024-08426-5 · ExternalCitation · doi-reference

RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer

10.1038/s41586-024-08508-4 · ExternalCitation · doi-reference

STING agonist-based ER-targeting molecules boost antigen cross-presentation

10.1038/s41586-025-08758-w · ExternalCitation · doi-reference

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade

10.1038/s41586-025-09655-y · ExternalCitation · doi-reference

mRNA vaccines engage unconventional pathways in CD8(+) T cell priming

10.1038/s41586-026-10353-6 · ExternalCitation · doi-reference

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

10.1038/s41587-022-01626-2 · ExternalCitation · doi-reference

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy

10.1038/s41587-024-02420-y · ExternalCitation · doi-reference

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

10.1038/s41590-018-0132-0 · ExternalCitation · doi-reference

Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth

10.1038/s41590-019-0321-5 · ExternalCitation · doi-reference

Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal

10.1038/s41590-020-0666-9 · ExternalCitation · doi-reference

Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine Malignancies

10.1038/s41590-022-01213-2 · ExternalCitation · doi-reference

Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping

10.1038/s41590-024-01884-z · ExternalCitation · doi-reference

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression

10.1038/s41590-025-02103-z · ExternalCitation · doi-reference

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination

10.1038/s41591-019-0410-x · ExternalCitation · doi-reference

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

10.1038/s41591-020-0856-x · ExternalCitation · doi-reference

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

10.1038/s41591-022-01829-9 · ExternalCitation · doi-reference

Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: A phase 2 trial

10.1038/s41591-022-01897-x · ExternalCitation · doi-reference

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: Phase 1 trial interim results

10.1038/s41591-022-01937-6 · ExternalCitation · doi-reference

Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma

10.1038/s41591-023-02345-0 · ExternalCitation · doi-reference

Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

10.1038/s41591-023-02363-y · ExternalCitation · doi-reference

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial

10.1038/s41591-023-02612-0 · ExternalCitation · doi-reference

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1/2 trial

10.1038/s41591-023-02785-8 · ExternalCitation · doi-reference

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1/2 trial

10.1038/s41591-024-02894-y · ExternalCitation · doi-reference

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

10.1038/s41591-025-03495-z · ExternalCitation · doi-reference

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

10.1038/s41591-025-03640-8 · ExternalCitation · doi-reference

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial

10.1038/s41591-025-03776-7 · ExternalCitation · doi-reference

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

10.1038/s41591-025-03876-4 · ExternalCitation · doi-reference

Nitric oxide mediated inhibition of antigen presentation from DCs to CD4(+) T cells in cancer and measurement of STAT1 nitration

10.1038/s41598-017-14970-0 · ExternalCitation · doi-reference

Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

10.1038/s43018-020-00143-y · ExternalCitation · doi-reference

c-Rel is a myeloid checkpoint for cancer immunotherapy

10.1038/s43018-020-0061-3 · ExternalCitation · doi-reference

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

10.1038/s43018-023-00668-y · ExternalCitation · doi-reference

An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy

10.1038/s43018-024-00760-x · ExternalCitation · doi-reference

Tumor-associated macrophages restrict CD8(+) T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment

10.1038/s43018-024-00775-4 · ExternalCitation · doi-reference

Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade

10.1038/s43018-025-00929-y · ExternalCitation · doi-reference

Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

10.1038/s43018-025-00940-3 · ExternalCitation · doi-reference

Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: A phase 1 trial

10.1038/s43018-025-00966-7 · ExternalCitation · doi-reference

Spatiotemporal analyses of the pan-cancer single-cell landscape reveal widespread profibrotic ecotypes associated with tumor immunity

10.1038/s43018-025-01039-5 · ExternalCitation · doi-reference

IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer

10.1056/evidoa2200167 · ExternalCitation · doi-reference

CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma

10.1056/nejmoa1807315 · ExternalCitation · doi-reference

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer

10.1073/pnas.2313693120 · ExternalCitation · doi-reference

Toll like receptor 7 expressed by Malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells

10.1080/2162402x.2018.1505174 · ExternalCitation · doi-reference

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

10.1084/jem.20101956 · ExternalCitation · doi-reference

NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing

10.1084/jem.20181454 · ExternalCitation · doi-reference

Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer

10.1084/jem.20190354 · ExternalCitation · doi-reference

Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses

10.1084/jem.20190801 · ExternalCitation · doi-reference

Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice

10.1084/jem.20201803 · ExternalCitation · doi-reference

Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis

10.1084/jem.20240957 · ExternalCitation · doi-reference

A pilot phase Ib study to evaluate tadalafil to overcome immunosuppression during chemoradiotherapy for IDH-wild-type glioblastoma

10.1093/noajnl/vdad088 · ExternalCitation · doi-reference

Eosinophilic inflammation promotes CCL6-dependent metastatic tumor growth

10.1126/sciadv.abb5943 · ExternalCitation · doi-reference

Neutrophil extracellular traps enhance macrophage killing of bacterial pathogens

10.1126/sciadv.abj2101 · ExternalCitation · doi-reference

Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy

10.1126/sciadv.adg3736 · ExternalCitation · doi-reference

Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils

10.1126/sciadv.adu5915 · ExternalCitation · doi-reference

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

10.1126/science.1232458 · ExternalCitation · doi-reference

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

10.1126/science.aad3018 · ExternalCitation · doi-reference

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity

10.1126/science.aao0505 · ExternalCitation · doi-reference

Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells

10.1126/science.aay5516 · ExternalCitation · doi-reference

An orally available non-nucleotide STING agonist with antitumor activity

10.1126/science.aba6098 · ExternalCitation · doi-reference

Distinct myeloid-derived suppressor cell populations in human glioblastoma

10.1126/science.abm5214 · ExternalCitation · doi-reference

CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers

10.1126/science.ade2292 · ExternalCitation · doi-reference

Deterministic reprogramming of neutrophils within tumors

10.1126/science.adf6493 · ExternalCitation · doi-reference

Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape

10.1126/science.adg1955 · ExternalCitation · doi-reference

RIG-I activation is critical for responsiveness to checkpoint blockade

10.1126/sciimmunol.aau8943 · ExternalCitation · doi-reference

Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics

10.1126/sciimmunol.aay6017 · ExternalCitation · doi-reference

NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists

10.1126/sciimmunol.aaz2738 · ExternalCitation · doi-reference

The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation

10.1126/sciimmunol.abc6998 · ExternalCitation · doi-reference

Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis

10.1126/sciimmunol.add5204 · ExternalCitation · doi-reference

Timing and location dictate monocyte fate and their transition to tumor-associated macrophages

10.1126/sciimmunol.adk3981 · ExternalCitation · doi-reference

Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4(+) T cell response

10.1126/sciimmunol.adq8843 · ExternalCitation · doi-reference

An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses

10.1126/sciimmunol.ads1328 · ExternalCitation · doi-reference

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy

10.1126/scitranslmed.3007974 · ExternalCitation · doi-reference

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

10.1126/scitranslmed.aaf2341 · ExternalCitation · doi-reference

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

10.1126/scitranslmed.abm1375 · ExternalCitation · doi-reference

Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma

10.1126/scitranslmed.abn6758 · ExternalCitation · doi-reference

Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted

10.1126/scitranslmed.adk1168 · ExternalCitation · doi-reference

Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment

10.1136/gutjnl-2021-326070 · ExternalCitation · doi-reference

Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer

10.1136/jitc-2019-000316 · ExternalCitation · doi-reference

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells

10.1136/jitc-2020-000691 · ExternalCitation · doi-reference

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections

10.1136/jitc-2022-005518 · ExternalCitation · doi-reference

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma

10.1136/jitc-2024-009352 · ExternalCitation · doi-reference

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

10.1158/0008-5472.can-08-1921 · ExternalCitation · doi-reference

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer

10.1158/0008-5472.can-09-1882 · ExternalCitation · doi-reference

Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody

10.1158/1078-0432.ccr-16-1784 · ExternalCitation · doi-reference

Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma

10.1158/1078-0432.ccr-17-0741 · ExternalCitation · doi-reference

Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

10.1158/1078-0432.ccr-21-1047 · ExternalCitation · doi-reference

Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase ib study

10.1158/1078-0432.ccr-22-2235 · ExternalCitation · doi-reference

Targeting MDSC differentiation using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma

10.1158/1078-0432.ccr-22-2495 · ExternalCitation · doi-reference

A novel peptidylarginine deiminase 4 (PAD4) inhibitor BMS-P5 blocks formation of neutrophil extracellular traps and delays progression of multiple myeloma

10.1158/1535-7163.mct-19-1020 · ExternalCitation · doi-reference

Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma

10.1158/2159-8290.cd-21-0425 · ExternalCitation · doi-reference

Hallmarks of cancer: New dimensions

10.1158/2159-8290.cd-21-1059 · ExternalCitation · doi-reference

Spatially segregated macrophage populations predict distinct outcomes in colon cancer

10.1158/2159-8290.cd-23-1300 · ExternalCitation · doi-reference

Tumor cells hijack macrophage-produced complement C1q to promote tumor growth

10.1158/2326-6066.cir-18-0891 · ExternalCitation · doi-reference

Impact of surgery-induced myeloid-derived suppressor cells and the NOX2/ROS axis on postoperative survival in human pancreatic cancer

10.1158/2767-9764.crc-23-0447 · ExternalCitation · doi-reference

PHOCUS: A phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma

10.1159/000533650 · ExternalCitation · doi-reference

VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment

10.1172/jci.insight.150735 · ExternalCitation · doi-reference

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy

10.1172/jci133055 · ExternalCitation · doi-reference

In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis

10.1172/jci157937 · ExternalCitation · doi-reference

The role of the complement system in cancer

10.1172/jci90962 · ExternalCitation · doi-reference

Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

10.1182/blood.2021013972 · ExternalCitation · doi-reference

Inhibition of the chemokine receptors CXCR1 and CXCR2 synergizes with docetaxel for effective tumor control and remodeling of the immune microenvironment of HPV-negative head and neck cancer models

10.1186/s13046-024-03240-3 · ExternalCitation · doi-reference

Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer

10.1200/jco.18.02031 · ExternalCitation · doi-reference

Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma

10.1200/jco.22.00343 · ExternalCitation · doi-reference

Canakinumab versus placebo in combination with first-line pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer: results from the CANOPY-1 trial

10.1200/jco.23.00980 · ExternalCitation · doi-reference

Randomized, open-label, phase III study of Tilsotolimod in combination with Ipilimumab versus Ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE-301)

10.1200/jco.24.00727 · ExternalCitation · doi-reference

Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

10.4049/jimmunol.1201654 · ExternalCitation · doi-reference

Yeast-derived particulate β-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to APC in cancer

10.4049/jimmunol.1501853 · ExternalCitation · doi-reference